480 related articles for article (PubMed ID: 12005089)
1. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
2. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole : a review of its use in the management of invasive fungal infections.
Scott LJ; Simpson D
Drugs; 2007; 67(2):269-98. PubMed ID: 17284090
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
7. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
[TBL] [Abstract][Full Text] [Related]
8. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
[TBL] [Abstract][Full Text] [Related]
10. [Voriconazole at Saint Louis Hospital (Paris): Analysis of two-years of compassionate use].
Papy E; Carde A; Ribaud P; Faure P; Touratier S
Presse Med; 2006 Feb; 35(2 Pt 1):251-2. PubMed ID: 16493359
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole: therapeutic review of a new azole antifungal.
Herbrecht R
Expert Rev Anti Infect Ther; 2004 Aug; 2(4):485-97. PubMed ID: 15482215
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.
Chu HY; Jain R; Xie H; Pottinger P; Fredricks DN
BMC Infect Dis; 2013 Feb; 13():105. PubMed ID: 23442261
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole therapy in children with cystic fibrosis.
Hilliard T; Edwards S; Buchdahl R; Francis J; Rosenthal M; Balfour-Lynn I; Bush A; Davies J
J Cyst Fibros; 2005 Dec; 4(4):215-20. PubMed ID: 16243008
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole in clinical practice.
Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
